Home
Search

Press Releases

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Featured Press Releases
BIO Statement on December 2025 ACIP Meeting
WASHINGTON, D.C. – Phyllis Arthur, Executive Vice President and Head of Health Policy and Programs of the Biotechnology Innovation Organization (BIO) released the following statement on the December 2025 ACIP meeting.“For decades, the CDC’s Advisory…
Learn more
BIO Statement on the Retirement of Richard Pazdur…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on reports of the retirement of Richard Pazdur from the US FDA.“Dr. Pazdur has dedicated decades of his career…
Learn more
BIO Statement on House Passage of Mikaela Naylon…
WASHINGTON, D.C. – The Biotechnology Innovation Organization (BIO) released the following statement on today’s passage of the Mikaela Naylon Give Kids a Chance Act in the House of Representatives.“The unanimous House passage of the Mikaela Naylon…
Learn more
All Press Releases
  • Show All
Search
Results
Event Tags
BIO Statement on CMS Announcement of First 10 Drugs Subject to Price Controls Under IRA
August 29, 2023
The Biden Administration today unveiled the first 10 prescription drugs that will be subject to price controls under the Inflation Reduction Act (IRA). Rachel King, BIO interim President and CEO, made the following statement: The Medicare price…
BIO FILES AMICUS BRIEF CHALLENGING FTC’S OVERREACH ON MERGER ENFORCEMENT THAT THREATENS DRUG DEVELOPMENT INNOVATION
August 24, 2023
BIO released the following statement from John Delacourt, BIO’s Deputy General Counsel, on BIO’s amicus brief opposing the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen: “The FTC’s current overreach in…
Dispute Panel 'Important Next Step' to Return to Science-Based Trade with Mexico
August 17, 2023
The following statement may be attributed to Nancy Travis, vice president of international affairs, BIO. “The Biotechnology Innovation Organization supports today’s action by the Office of the U.S. Trade Representative to request formation of a…
How BIO Used New Social Sharing Technology to Drive High Engagement Leading Up to the 2023 BIO International Convention
August 9, 2023
Using organic social sharing techniques and tools, BIO’s social media team was able to drive record levels of engagement for their premier event. For social media managers, successfully reaching an organization’s member companies, partners, and…
Majority of U.S. Voters Support Streamlined Biotech Regulations
August 3, 2023
New BIO/Morning Consult survey shows strong support for biotech innovation and its role in addressing critical global challenges.The majority of U.S. voters (62%) hold a favorable opinion of biotechnology and view its benefits as important,…
Now is the Time to Seize Bioeconomy Opportunities in Farm Bill
July 26, 2023
The next farm bill offers opportunities to invest in long-term food security, climate resiliency and growing the nation’s burgeoning bioeconomy, according to the Biotechnology Innovation Organization, which has submitted recommendations to the House…
PAHPA committee votes "important step forward" in public health preparedness
July 20, 2023
Two Congressional committees this week pushed through legislation to reauthorize the Pandemic All Hazards and Preparedness Act (PAHPA). Following the votes, Phyllis Arthur -- Senior Vice President, Infectious Diseases & Emerging Science…
Reasonable Pricing Clause in PAHPA Undermines Ability To Protect Country And Prepare for Future Pandemics
July 3, 2023
The Senate HELP Committee today released a discussion draft of legislation to reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA). BIO represents many small- and mid-size companies that are at the heart of the type of public-private…
New CMS guidance a "missed opportunity" for future medical innovation, patients
June 30, 2023
The Centers for Medicare & Medicaid Services (CMS) today released its guidance for the Drug Price Negotiation Program (Negotiation Program) under the Inflation Reduction Act of 2022 (IRA). John Murphy, BIO’s Chief Policy Officer, made the…
BIO: Delay of R&D Tax Burden is Positive Step, Permanent Repeal Still Needed
June 15, 2023
The House Ways & Means Committee has approved a bill that includes language to delay retroactively through 2025 the mandatory capitalization of research and development expenses, which took effect in tax year 2022. The Tax Cuts and Jobs Act of…
gooddaybio-cover-final
Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy. 

Sign Up Today